Persons Reported to be living with HIV infection and with AIDS reported
Year Adults/Adolescents Children Under 13 Years old Total Cumulative Totals
  HIV AIDS HIV AIDS HIV AIDS Adults / Adolescents Children Under 13 Years old Total
2000 18,774 35,195 165 475 18,939 35,670 53,969 640 54,609
2001

22,844

38,306

 201 436 23,045 38,742 61,150 637 61,787
2002 27,638 40,607 275 408 27,913 41,015 68,245 683 68,928
                   

 

 

HIV Infection Cases  from areas with confidential HIV infection reporting
Year   Cumulative Totals
    Adults / Adolescents Children Under 13 Years old Total
2000 5,810 19,137 185 19,322
2001 5,744 23,325 232 23,557
2002 6122 27,638 408 27,913
         

 

Adult/Adolescent HIV infection and AIDS cases reported in the United States
Year Males Females
  HIV AIDS HIV AIDS
2000 3,616 3,487 2,148 1,465
2001 3,657 3,616 2,027 1,488
         

 

New Pediatric AIDS cases reported

Year
2000 24
2001 34
   
   


 

Cumulative AIDS Cases

Cumulative Number of AIDS Cases, Reported through 2002 90,233
Cumulative Number of Adult/Adolescent AIDS Cases, Reported through 2002 88,760
Cumulative Number of AIDS Cases in Children <13, Reported through 2002 1,473

Distribution of Cumulative Adult/Adolescent AIDS Cases by Gender, Reported through June 2002
  FL USA
Men 66,800 680,909
Women 19,520 146,298
Total 86,320 827,208

 

New AIDS Cases

New AIDS Cases, Reported through 2002 5,058
New Adult/Adolescent AIDS Cases, Reported in 2001 5,104
New AIDS Cases in Children <13, Reported through December 2001 34

Distribution of New Adult/Adolescent AIDS Cases by Gender, Reported in 2001
  FL USA
Men 3,616 31,901
Women 1,488 11,082
Total 5,104 42,983

 

Persons Living with AIDS

Estimated Number of Persons Living with AIDS at the End of 2002 41,015
Estimated Number of Adults/Adolescents Living with AIDS at the End of 2002 40,607
Estimated Number of Children Living with AIDS at the End of 2002 408
HIV Infection Cases Reported in 2002 6,122

 

Total Deaths Reported through 2000, due to AIDS = 44,434
HIV Reporting Requirements ?   Yes, Name Based.
 
HIV Testing Options?  Anonymous and Confidential testing
Definitions: Anonymous test: Individual does NOT use their name, and a name is not associated with test result. Anonymous tests are offered at anonymous testing centers, available in many, but not all, states.
Confidential test: Individual DOES use their name. If test is positive, individual's name will be known to their health care provider and, potentially, to other health care professionals and, in some cases, your state's Department of Health.
 
HIV Testing for Mothers and Newborns
Voluntary or Mandatory Testing?  Providers required to offer HIV test, Health care providers are required by law to offer HIV testing to pregnant women as a standard of care. Law permits providers to test newborns for HIV if medically necessary and parent(s) are not available to provide consent.
Voluntary HIV Testing: All states and the District of Columbia have certified to the CDC that they have measures in place to implement the CDC's 1995 recommendations on HIV counseling and testing of pregnant women.  The CDC's 1995 recommendations state that HIV testing of pregnant women and infants should be voluntary and providers must obtain informed consent for testing as required by their state laws.  Voluntary testing is noted if the state follows the CDC guidelines but does not have specific guidelines for testing of mothers and newborns.
 
Status of State Medicaid Expansion Efforts for People with HIV
Approved 1115 Waiver, TWWIIA demonstration? NO, Has considered or is considering an 1115 Waiver to expand Medicaid eligibility to people with HIV.
Definitions: 1115 Waivers: Section 1115 of the Social Security Act authorizes the executive branch of the Federal government to waive the statutory and regulatory provisions of the Medicaid program. States have used "1115 waivers" to make changes in eligibility, benefits, and other areas of their Medicaid programs. The Centers for Medicare and Medicaid Services (CMS--formerly known as the Health Care Financing Administration) and several states have been analyzing the implications of expanding Medicaid eligibility to people with HIV prior to disability through the use of Section 1115 waivers of the Social Security Act. To use 1115 waivers, states face several challenges, particularly the need to demonstrate "budget neutrality" to the Medicaid program - that the costs of an expansion over a designated period of time (usually 5 years) would not exceed the costs to Medicaid in the absence of the expansion.
Ticket to Work/Work Incentives Improvement Act of 1999: TWWIIA expanded State options under Medicaid by creating new Medicaid buy-in options for working individuals with disabilities and extended Medicare cover-age for working individuals with disabilities. The Act also authorized state demonstration programs to provide Medicaid to workers with potentially severe disabilities, including HIV/AIDS, who are not yet disabled but whose health conditions could be expected to cause disability.
Notes: Most people with HIV who qualify for Medicaid do so by meeting the program’s income and disability standards once their illness has already progressed. Many low income people with HIV may be faced with of having their eligibility postponed until they become disabled, even though there are therapies available that may prevent disability and national treatment guidelines recommend access to early treatment. 1115 Waivers and TWWIIA demonstrations are two ways in which states have sought to address this limitation.

 
Sterile Syringe Exchange Programs?  No
Notes: U.S. totals include data from the United States (50 states and the District of Columbia), and from U.S. dependencies, possessions, and independent nations in free association with the United States.
Definitions: Programs in operation: includes both state-sanctioned syringe exchange programs and non-sanctioned programs. Because their operation may not necessarily be authorized, it is difficult to account for an exact number of syringe exchange programs operation across the country; therefore, the list may not be comprehensive.
 
STD/HIV/AIDS Education Requirement?  Yes, Must cover abstinence
 
Minors' Right to Consent to HIV/STD Services?  Yes, State explicitly classifies HIV/AIDS as an STD or infectious disease, for which minors may consent to testing and treatment.

 

Total Ryan White Funding, FY2000   $159,087,404 FY2002  $192,878,364

 

CDC HIV Prevention Funding for States
 FY2001 $21,016,382

 FY2003   $19,734,925

 

Total Federal and State Funding for ADAP, FY2001  $73,163,122

Definitions: ADAPs: AIDS Drug Assistance Programs (ADAPs), authorized under Title II of the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act, provide HIV-related prescription drugs to underinsured and uninsured individuals living with HIV/AIDS. Each state or territory administers its own ADAP.

 

AIDS Drug Assistance Programs (ADAPs)
Source Kaiser Family Foundation

Total ADAP Clients Served, June 2002  
  FL
#		 US
#
   10,364 80,035

 
ADAP Clients Served by Sex, June 2002  
  FL
#		 FL
%		 US
#		 US
%
  Male 7,462 72 62,034 78
  Female 2,902 28 16,702 21
  Total 10,364 100 79,531 100

 
ADAP Clients Served by Race/Ethnicity, June 2002  
  FL
#		 FL
%		 US
#		 US
%
  White 2,798 27 29,426 37
  Black 4,975 48 26,245 33
  Hispanic 2,487 24 19,883 25
  Asian/Pacific Islander 0 1 0 1 795 1
  American Indian/Alaskan Native 0 1 0 1 795 1
  Other 0 1 0 1 795 1
  Total 10,364 100 79,531 100

 
ADAP Clients Served by Age, June 2002  
  FL
#		 FL
%		 US
#		 US
%
  <13 years old 207 2 795 1
  13-19 years old 0 0 0 1 0 1
  20-44 years old 6,737 65 50,105 63
  >44 years old 3,627 35 27,836 35
  Total 10,364 102 79,531 100

 

ADAP Clients Served by Income, June 2002  
  FL
#		 FL
%		 US
#		 US
%
  <100% FPL 9,639 93 38,175 48
  101-200% FPL 622 6 26,245 33
  201-300% FPL 104 1 8,748 11
  301-400% FPL 0 0 3,181 4
  >400% FPL 0 0 1,591 2
  Total 10,364 100 79,531 100

 
Insurance Coverage of ADAP Clients, June 2002  
  FL
#		 FL
%		 US
#		 US
%
  Medicaid 0 0 0 10
  Medicare 0 0 0 6
  Private 104 1 0 13

 
National ADAP Budget, Total Federal and State Sources, FY 2002  
  FL
$		 US
$
   79,644,216 878,610,754

 
National ADAP Budget by Source, FY 2002  
  FL
$		 FL
%		 US
$		 US
%
  ADAP Earmark 68,567,784 86 619,830,000 71
  Title II Base 2,076,432 3 28,886,192 3
  State 9,000,000 11 160,385,979 18
  Title I 0 0 19,736,619 2
  Other Federal 0 0 30,941,439 4
  ADAP Supplemental Grants 0 0 19,170,000 2
  Total 79,644,216 100 878,610,754 100

 
Total ADAP Drug Expenditures, June 2002  
  FL
$		 US
$
   5,834,880 70,705,142

 
ADAP Drug Expenditures by Drug Class, June 2002  
  FL
$		 FL
%		 US
$		 US
%
  Nucleoside Reverse Transcriptase Inhibitors 3,359,823 58 31,486,146 49
  non-Nucleoside Reverse Transcriptase Inhibitors 725,872 12 7,940,575 12
  Protease Inhibitors 1,292,188 22 16,433,502 25
  Opportunistic Infections/Other 456,997 8 9,015,329 14
  Total 5,834,880 100 64,875,793 100

 
Total ADAP Prescriptions Filled, June 2002  
  FL
#		 US
#
   NA 2 257,279

 
ADAP Prescriptions Filled by Drug Class, June 2002  
  FL
#		 FL
%		 US
#		 US
%
  Nucleoside Reverse Transcriptase Inhibitors NA 2 NA 2 83,166 36
  non-Nucleoside Reverse Transcriptase Inhibitors NA 2 NA 2 23,933 10
  Protease Inhibitors NA 2 NA 2 33,813 15
  Opportunistic Infections/Other NA 2 NA 2 87,746 38
  Total NA 2 NA 2 228,771 100

 
Federal ADAP Funds Used for Insurance Purchasing/Maintenance, FY 2002  
  FL
$		 US
$
   NA 18,486,544

 
ADAP Formularies, Number of Medications by Drug Class, 2002  
  FL
#		 US
#
  Nucleoside Reverse Transcriptase Inhibitors 9 NA
  Protease Inhibitors Covered 6 NA
  Non-nucleosides Covered 3 NA
  OI Prophylaxis Covered 8 NA
  Other Medications Covered 27 NA
  Total 53 NA

 
ADAP Emergency Cost Containment Measures, February 2003  
  FL
 		 US
 
  Has ADAP Emergency Cost Containment Measures in Place No 16 Yes
  Notes